Loading...
Loading...
CRSP| Name | Value |
|---|---|
| Revenues | 70.0M |
| Cost of Revenue | 44.6M |
| Gross Profit | 25.4M |
| Operating Expense | 120.6M |
| Operating I/L | -95.2M |
| Other Income/Expense | 18.4M |
| Interest Income | 18.4M |
| Pretax | -76.8M |
| Income Tax Expense | 0.9M |
| Net Income/Loss | -77.7M |
CRISPR Therapeutics AG is a gene editing company that develops gene-based medicines using its proprietary CRISPR/Cas9 platform. The company's portfolio includes therapeutic programs for hemoglobinopathies, oncology, regenerative medicine, and rare diseases. Its lead product candidate, CTX001, is an ex vivo CRISPR gene-edited therapy for transfusion-dependent beta-thalassemia and severe sickle cell disease. Additionally, the company develops gene-edited allogeneic CAR-T investigational therapies for various malignancies and solid tumors, as well as immune-evasive stem cell-derived product candidates for type 1 diabetes. CRISPR Therapeutics AG generates revenue through strategic partnerships with companies like Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and others.
